Nuvasive Inc (NUVA) exceeds sales estimates
Spine surgery products maker NuVasive Inc. (NUV) said its first-quarter loss expanded, however revenue increased by 54 percent far surpassing Wall Street estimates. With a FusionIQ master technical score of 87 (out of a possible 100) and our projected target of $47.00 - NUVA offers a good intermediate term trading opportunity.  Given yesterday's large price spike we would suggest average cost buying on weakness makes the most sense.

Comments
Leave a comment
Name
Email Address
URL
Remember personal info?
Comments
Blog Home
RSS Feed
Categories
Barron's
Breakouts/Breakdowns
ChartWatch
Company in the News
Equity Timing Signals (Buy/Sell)
Market Data
Media
Sector Group Rankings
Short Squeeze Screen
Stock Analysis
Total Stocks Rankings
Archives
April 2008
March 2008
February 2008
January 2008
December 2007